;
Home | Accelerate@Babraham | Meet the experts

Accelerate@Babraham Selected Experts

Thank you to all of our experts for their ongoing support of the Accelerate@Babraham programme. Find out more about some of them below.

Chris Torrance

Dr Chris Torrance is a cancer researcher and entrepreneur. In 2007 he founded Horizon Discovery to translate advances in human genome editing.

Andy Richards

Andy Richards is an entrepreneur and investor with an established track record in founding and scaling up innovative Biotech and Healthtech companies in the UK.

Jonathan Milner

Jonathan Milner is an experienced entrepreneur and investor who is passionate about supporting UK life science and high-tech start-ups.

David Grainger

Following an academic career at Cambridge University spanning 20 years, leading a world-renowned group, David joined Index Ventures.

Chris Poole

Chris has 25 years’ experience in finance, holding senior positions at a variety of organisation types ranging from business start-ups to a FTSE 250 company.

Jo Parfrey

Jo Parfrey is an experienced and successful investment professional with more than 10 years in the private equity industry.

Joanne Hackett

Professor Joanne Hackett is the Chief Commercial Officer at Genomics England and lead member of the Business and Investment Committee.

Nikola Novcic

Project Leader in Healthcare for Boston Consulting Group, Nikola has extensive knowledge of the Biopharma and MedTech industry.

Bobby Anderson

Bobby Anderson is a Vice President at Silicon Valley Bank in their Life Science and Healthcare practice.

Khatereh Ahmadi

Khatereh Ahmadi has worked in the biotech/pharma industry for 15 years. Previous to her current role at MSD/Merck as Executive Director, she was a co-founder and CEO of reViral Ltd.

Neil Torbett

Neil joined PhoreMost as Chief Business Officer in January 2017 and has responsibility for all operational and commercial activities.

Olivia Cavlan

Prior to joining SV Health Investors, Olivia was a Partner at McKinsey & Company where she focused on Pharmaceuticals, Healthcare, Advanced Analytics, and Real World Evidence.

Brian Burke

Brian is an experienced life sciences business leader with a strong track record of success in both strategy and execution. He has benefited enormously from being part of the early NGS and gene editing revolutions.

Natalia Novac

Natalia Novac is a part of the Emerging Technology and Innovation Group and is responsible for search and evaluation of novel healthcare technologies across all Eli Lilly indications in Europe.

Tim Luker

Tim Luker is currently VP External Innovation at Eli Lilly. He leads Lilly's external advancing innovation process within Global Corporate Business Development.

Steve Jackson

Steve Jackson FRS, FMedSci is University of Cambridge and Cancer Research UK Professor of Biology, and Head of Cancer Research UK Laboratories at the Gurdon Institute.

Jane Dancer

Jane has over 15 years’ experience in Business Development. Prior to joining F-star she was VP Business Development at Cellzome and Director, Business Development at MedImmune Ltd.

Steve Dowd

Steve has over 20 years biotechnology and pharmaceutical industry experience in both business development and R&D. He is currently Senior Director of Business Development at Kymab.

Laura Ferguson

Laura is passionate about supporting life science innovation and connecting the early innovation ecosystem. She has a background in academia and experience in entrepreneurship and finance.

Tim Minshall

Tim is the inaugural Dr John C Taylor Professor of Innovation at the University of Cambridge, Head of the Institute for Manufacturing and Head of the IfM’s Centre for Technology Management.

Eliot Forster

Eliot has more than 25 years of experience in the pharmaceutical and biotechnology industry and previously served as Chief Executive Officer of Immunocore, Creabilis Therapeutics and Solace Pharmaceuticals Inc.

Jeremy Griggs

Jeremy is a Senior Director in GSK R&D's Worldwide Business Development Team, with a focus on identifying and evaluating innovative emerging science, drugs and technologies.

Vishal Gulati

Vishal Gulati is a venture partner at Draper Esprit a leading European venture capital firm. His investment interests include healthtech, omics and synthetic biology.

Anna Williamson

Anna Williamson is a Director of Business Development at Roche Pharma Partnering and the Head of Roche’s Cambridge Innovation Hub providing business development support.

Hermann Hauser

Serial Entrepreneur and Co-founder of Amadeus Capital Partners, Dr Hermann Hauser KBE has wide experience in developing and financing companies in the information technology sector.

David Ford

David is an Oxford-based life sciences angel investor. Since 2016 he has been focused on early-stage investing, managing the Arrowfield Capital syndicate.

Paul Wallace

Paul has over 25 years’ leadership experience in business development. Currently he is CBO for Mission Therapeutics, located on the Babraham Research Campus.

Sarah Brereton

As Director of Limewash, a strategic marketing agency, Sarah helps clients understand their customers, propositions and processes better, before working with them to develop the right mix of communications to deliver value.

Kate Moss

Kate is a Management Consultant in the life sciences Industry specialised in helping companies implement strategy through the development of capabilities and positive engagement which deliver the desired performance and value.

Keith Blundy

Keith joined STORM Therapeutics as CEO in January 2017. Prior to STORM, Keith was Chief Executive of Cancer Research Technology Ltd, the commercial arm of Cancer Research UK, where he drove development to become a global leader.

Anne Tiney

With an HR background gained in various drug discovery organisations, Anne joined Mission Therapeutics in 2016 as Vice President, Human Resources.

David Holbrook

David Holbrook is a qualified physician who has spent thirty-five years in medicine and medical innovation, and the last twenty in life sciences spinout investing, principally from academia.

Marcus Yeo

Marcus Yeo is a founder and CEO of DefiniGEN. He is an experienced Company Director and life scientist.

Charli Batley

Having completed my PhD in Biochemistry at Reading, I very quickly decided that research was not for me. I became a sales rep, where I met Chris Torrance just after he had started Horizon Discovery.

Jackie Hunter

Jackie Hunter is currently a Board Director of BenevolentAI, a UK unicorn company that uses artificial intelligence to disrupt the drug discovery and development process.

Allan Marchington

Allan Marchington is a founder and Managing Partner at Bridge Valley Ventures a UK based Life Science investor which was established by LifeArc of the UK leading medical charities.

Hugo Christie

I am a personable, commercial and pragmatic lawyer who can provide you with strategic advice taking into account; how your business operates; your approach to risk; and ultimately, helping you achieve your objectives.

Jelena Aleksic

Jelena is a geneticist turned entrepreneur. She is currently the Director of European Partnerships at Raremark, working to accelerate therapeutics development for patients with rare disease.

Sam Barker

Sam Barker is the Business Development and Alliance Manager at PhoreMost Ltd. Sam joined PhoreMost in 2016 as a scientist in the drug discovery team.

Michael Anstey

Dr Michael Anstey is an Investment Director at Cambridge Innovation Capital specialising in healthcare investments.

Pablo Lubroth

Pablo joined Midven in July 2018 as Investment Manager working on the UK Innovation & Science Seed Fund, focusing on the Synthetic Biology portfolio.

Daniel Bridges

Daniel is a specialist in corporate strategy, transformation management and capital planning, focused on supporting the founders of high value SMEs through the start-up and scale-up growth phases.

Pierre Peotta

Pierre has over ten years of experience in Marketing, Communications and Sales in the Life Science sector, built up across a range of businesses.

Peter Crane

Peter is a scientist, who a couple of years ago made the plunge into the world of technology. As such, he approaches the world of technology investing scientifically with a focus on evidence.

Mariam Mirza

Mariam is a Business Psychologist Consultant at OE Cam, focusing on the assessment and development of individuals and teams.

Mark Lees

Mark has worked in a range of business consulting roles and biotech companies, including a UCL spin out.

KAI STOEBER

Kai Stoeber is Senior Director, External Innovation at Johnson & Johnson Innovation.

STEWART KAY

Stewart joined Crescendo in 2019 as Chief Business Officer and has over 20 years’ experience in business development.

PEJU OSHISANYA

Peju has worked in the clinical research industry for over 15 years during which she has acquired wide-ranging experience.

JANE OSBOURN

Jane was an early employee of Cambridge Antibody Technology, which became MedImmune, the global biologics research and development arm of AstraZeneca.

Jill Reckless

In April 2013, Jill Reckless co-founded RxCelerate Ltd with David Grainger, an out-sourcing drug discovery and development platform.

MARCO CERATO

Marco joined the Mundipharma network of independent associated companies in 2018 further enhance our external partnerships and medicine pipeline.

John Trainer

John is leader of AstraZeneca’s Partnering and Strategy group, which focuses on business deals ranging from acquisitions and clinical collaborations to licensing agreements and new industry partnerships.

Rebecca Todd

Rebecca began venture investing in 2006 while at Oxford Capital, and went on to become Director, Healthcare Ventures at Imperial Innovations (now Touchstone Innovations).

Christine Martin

As Head of Life Science Investment within the Life Sciences team at Cambridge Enterprise Christine focuses on drug discovery and is responsible for a broad portfolio.

Abel Ureta-Vidal

For the last 11 years Abel has been one driving force within the executive team at Eagle as CEO, and since May 2018 as Chief Product Officer.

Lilian Alcaraz

Lilian is Senior Director, New Ventures and Transactions lead for Neuroscience, at Johnson & Johnson Innovation.

Daria Donati

Daria Donati is leading the Cytiva and Bioprocess Business inorganic pipeline, driving growth through M&A and strategic investments for the bioprocess business.

Contact us

BABRAHAM RESEARCH
CAMPUS

(+44) 1223 496 000
info@babraham.co.uk

Babraham Bioscience Technologies Ltd
Babraham Research Campus
Cambridge
CB22 3AT, United Kingdom

Press Enquiries

Limewash
01223 813 557
info@limewash.co.uk

Subscribe to our mailing list

Please enter your first name
Please enter your surname
Please enter your email address
Submit
; ;